Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0165)
Name
Ebselen
Synonyms
ebselen; 60940-34-3; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; 2-phenylbenzo[d][1,2]selenazol-3(2H)-one; Ebselenum; 2-phenyl-1,2-benzoselenazol-3-one; SPI-1005; Ebselene; Ebseleno; Ebselen [INN]; Ebselene [French]; Ebselenum [Latin]; Harmokisane; Ebseleno [Spanish]; C13H9NOSe; PZ 51; DR-3305; PZ-51; PZ51; MLS000028488; DR3305; CCRIS 3714; 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl-; 2-Phenyl-1,2-benzisoselenazolin-3-one; SMR000058445; UNII-40X2P7DPGH; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; CHEMBL51085; NSC 639762; Prestwick_1057; SPI-3005; Prestwick0_000740; Prestwick1_000740; Prestwick2_000740; Prestwick3_000740; Spectrum2_001441; Spectrum3_000799; Spectrum4_000445; Spectrum5_001713; Lopac-E-3520; MFCD00210937; NSC639762; NSC-639762; NSC-757883; 40X2P7DPGH; Lopac0_000541; NCGC00015412-06; BSPBio_000700; BSPBio_001342; BSPBio_002538; CPD000058445; KBioGR_000062; KBioGR_000830; KBioSS_000062; DivK1c_000951; SPBio_001301; SPBio_002639; CAS-60940-34-3; MLS001148646; BPBio1_000770; DTXSID7045150; BCBcMAP01_000149; CHEBI:77543; HMS502P13; KBio1_000951; KBio2_000062; KBio2_002630; KBio2_005198; KBio3_000123; KBio3_000124; KBio3_001758; NINDS_000951; E 3520; Bio2_000062; Bio2_000542; HMS1361D04; HMS1570C22; HMS1791D04; HMS1989D04; HMS2052N09; CCG-39161; AC-1124; IDI1_000951; IDI1_033812; QTL1_000035; NCGC00015412-01; NCGC00015412-02; NCGC00015412-03; NCGC00015412-13; NCGC00024072-03; NCGC00024072-04; NCGC00024072-05; NCGC00178610-01; NCGC00178610-02; NCGC00178610-03; AB00053217; EU-0100541; MLS-0003066.0001; BRD-K29359156-001-06-1; DR 3305; RP 60931; SR-01000003081; AC1L1FDW; CID3194; SPI1005; Ebselen (C5); nchembio.109-comp1; 2-phenyl-1,2-benzoselenazol-3(2h)-one; LS-33527; SAM001247071; EBSELEN [JAN]; EBSELEN [MI]; EBSELEN [MART.]; Opera_ID_1643; EBSELEN [WHO-DD]; Ebselen, cysteine modifier; cid_3194; C042986; SCHEMBL33829; MLS001424261; MLS006010108; E3520_SIGMA; I09-1611; DTXCID5025150; BDBM34233; GTPL10583; HMS2097C22; HMS2235A11; HMS3394N09; HMS3402D04; HMS3649O05; HMS3714C22; HMS3873N13; KUC112559N; Pharmakon1600-01501188; BCP17134; EX-A1447; SPI-1005;PZ-51; Tox21_110140; 2-Phenyl-benzo[d]isoselenazol-3-one; DAP001372; HB0270; NSC757883; s6676; AKOS015898841; CS-5534; DB12610; LP00541; NC00431; SDCCGSBI-0050524.P004; KSC-325-014; NCGC00015412-04; NCGC00015412-05; NCGC00015412-07; NCGC00015412-08; NCGC00015412-09; NCGC00015412-10; NCGC00015412-11; NCGC00015412-12; NCGC00015412-21; phenyl-1,2-benzisoselenazol-3(2H)-one; 2-phenyl-1,2-benzisoselazol-3(2H)-one; HY-13750; SY052687; SBI-0050524.P003; 2-phenyl-1,2-benzisoselenazole-3(2H)-one; 2-phenyl-1,2-benzoisoselenazole-3(2H)-one; E0946; FT-0759332; 2-phenyl-1,2-benzoisoselenazole-3-(2H)-one; 2-Phenyl-benzo[d]isoselenazol-3-one(Ebselen); C75847; AB00053217_25; A868855; Q5332073; SR-01000003081-2; SR-01000003081-7; SR-01000003081-8; BRD-K29359156-001-23-6; SR-01000003081-10; SR-01000003081-14

    Click to Show/Hide
Structure
3D MOL
2D MOL
Formula
C13H9NOSe
IUPAC Name
2-phenyl-1,2-benzoselenazol-3-one
Canonical SMILES
C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2
InChI
InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
InChIKey
DYEFUKCXAQOFHX-UHFFFAOYSA-N
PubChem CID
3194
Full List of Ferroptosis Target Related to This Drug
Natural resistance-associated macrophage protein 2 (SLC11A2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Driver
Responsed Disease Traumatic brain injury ICD-11: NA07
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model hBCs (Brain cells)
In Vivo Model
Male Sprague-Dawley (SD) rats were introduced into research, for the present SAH model a total of 383 rats, weighing 250-300 g, were purchased from the Animal Center of Chongqing Medical University. The adult male SD rats assigned to SAH model procedures were randomly divided into several groups. The rats assigned to SAH model procedures were randomly divided into the groups, first to determine the expression of hepcidin, DMT1, FPN1, and GPX4, the main regulator of ferroptosis, and to subsequently select the most suitable timing for drug injections. Second, adult male SD rats were randomly divided into the groups to determine the significant preoperative doses of ebselen, heparin and OSM in terms of their effects on hepcidin, DMT1, FPN1, and GPX4 for further study. Lastly, male SD rats were randomly divided into the groups to determine the effects of hepcidin and DMT1 on iron metabolism, ferroptosis, and EBI, by using heparin, ebselen and OSM as the experimental interventions.

    Click to Show/Hide
Response regulation Inhibition of DMT1 by ebselen could suppress iron accumulation and lipid peroxidation, and thereby alleviate ferroptosis and early brain injury (EBI) in SAH rats. Heparin downregulated the expression of hepcidin and DMT1, increased FPN1, and exerted protective effects that were equivalent to those of ebselen on ferroptosis and EBI. In addition, OSM increased the expression of hepcidin and DMT1, decreased FPN1, and aggravated ferroptosis and EBI, while the effect on ferroptosis was reversed by ebselen.
References
Ref 1 Hepcidin Promoted Ferroptosis through Iron Metabolism which Is Associated with DMT1 Signaling Activation in Early Brain Injury following Subarachnoid Hemorrhage. Oxid Med Cell Longev. 2021 Dec 27;2021:9800794. doi: 10.1155/2021/9800794. eCollection 2021.